SOURCE: VIVALIS

April 30, 2008 14:05 ET

VIVALIS ANNOUNCES THE FILING OF ITS FIRST ANNUAL REGISTRATION DOCUMENT

NANTES, FRANCE--(Marketwire - April 30, 2008) - VIVALIS (Euronext Paris: VLS), announces the filing of its first annual Registration Document under the number R.08-051 dated April 30, 2008 , with the Autorité des Marchés Financiers ("AMF").

The registration document is available free of charge at VIVALIS' head office, 6 rue Alain Bombard 44800 Saint-Herblain and in electronic form on the Company's web site (www.vivalis.com) and on the web site of the AMF (www.amf-france.org)

*******************

Next press release:

13 August 2008, after closure of the Euronext Paris market: Turnover for the 2nd quarter of 2008

About VIVALIS (www.vivalis.com)

VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. VIVALIS's expertise and intellectual property are exploited in three main areas:

1. The development and manufacturing of vaccines. VIVALIS offers research and commercial licences for its EBx® embryonic stem cell lines to pharmaceutical and biotechnology companies for the production of viral vaccines.

2. The development of production systems for recombinant proteins and monoclonal antibodies. VIVALIS licences its EBx® embryonic stem cell lines for the production of recombinant proteins to biotechnology and pharmaceutical companies.

3. The construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules (hepatitis C).

Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group (1,450 employees), the second largest group worldwide in animal genetic selection. VIVALIS has established numerous partnerships with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Novartis Vaccines, Kaketsuken, Merial and SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES cluster of competitive excellence.

Euronext Paris Compartment C - FR0004056851

Reuters: VLS.PA - Bloomberg: VLS FP

Investor relations:

VIVALIS

Franck Grimaud, C.E.O.

Email: investors@vivalis.com

NewCap

Financial Communication Agency

Steve Grobet / Emmanuel Huynh

Tel.: +33 (0) 1 44 71 94 91

Email: vivalis@newcap.fr

This information is provided by HUGIN

Contact Information